[Sedaily] “Re-pursuing the acquisition of a Clinical Trial consignment agency… Taking the lead to Decentralized Clinical Trial.”
“For a domestic blockbuster new drug to be created, domestic contract research organizations (CROs) must first secure global-level capabilities. This is why domestic CROs must not be complacent and must head to the global market.”
Moon-Tae Yoon, CEO of C&R Research (359090), Korea’s first and largest CRO, met with the Seoul Economic Daily at its headquarters in Daechi-dong, Gangnam-gu, Seoul on the 18th and spoke about the role of domestic CROs in achieving the government’s goal of becoming one of the six major pharmaceutical and bio powerhouses. CEO Yoon introduced clinical practice to the domestic market in the 1980s and first established the concept of CRO. CEO Yoon is pursuing global expansion rather than remaining the number one CRO in sales. Having worked as a pharmacist and working at Dong-A Pharmaceutical and LG Chemical, he created a Korean-style preclinical and clinical process by directly referring to overseas cases.
